References
- Cho JD, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
- Marques LPJ, Flores JT, Barros Junior OO, et al. Epidemiological and clinical aspects of urinary tract infection in community-dwelling elderly women. Braz J Infect Dis. 2012;16:436–441.
- Boyko EJ, Fihn SD, Scholes D, et al. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005;161:557–564.
- Wilke T, Böttger B, Berg B, et al. Healthcare burden and costs associated with urinary tract infections in type2 diabetes mellitus patients: an analysis based on a large sample of 456,586 German patients. Nephron. 2016;132:215–226.
- Nitzan O, Elias M, Chazan B, et al. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diab Metab Synd Obes. 2015;8:129–136.
- Pandey J, Tamrakar AK. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018). Expert Opin Ther Pat. 2019;29:369–384.
- Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18:295–311.
- Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61:2118–2125.
- Soh PN, Vidal F, Huyghe E, et al. Urinary and genital infections in patients with diabetes: how to diagnose and how to treat. Diabetes Metab. 2016;42:16–24.
- Alvisi S, Gava G, Orsili I, et al. Vaginal health in menopausal women. Medicina (B Aires). 2019;55(10):615. .
- Lega IC, Bronskill SE, Michael A, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019;21:2394–2404.
- Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. Infections in patients with diabetes mellitus. J Clin Med. 2019;76:1–41.
- Yokoyama H, Nagao A, Watanabe S, et al. Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes. J Diabetes Investig. 2019;10::439–4450.
- US Food and Drug Administration, drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Silver Spring (MD): US Food and Drug Administration; 2015. Available from: www.fda.gov/Drugs/DrugSafety/ucm475463.htm
- Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348–355.
- Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–794.
- Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274.
- Shen J, Yang J, Zhao BA. Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use. Diabetes Ther. 2019;10:1043–1050.
- Puckrin R, Saltiel MP, Reynier P, et al. SGTL-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55:503–514.
- Dave CV, Schneeweiss S, Kim D, et al. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: A population-based cohort study. Ann Intern Med. 2019;171:248–256.
- Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Posgraduate Med. 2016;128:409–417.
- Turan H, Serefhanoglu K, Torun AN, et al. Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus. Jpn J Infect Dis. 2008;61:236–238.
- Renko M, Tapanainen P, Tossvainen P, et al. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34:230–235.
- Nicolle LE. The paradigm shift to non-treatment of asymptomatic bacteriuria. Pathogens. 2016;5:38.
- Cameron AP, Campeau L, Brucker BM, et al. Best practice policy statement on urodynamic antibiotic prophylaxis in the non-index patient. Neurourol Urodyn. 2017;9999:1–12.